Simplified oral antibiotic regimen for pyogenic flexor tenosynovitis - 01/10/26
Abstract |
Introduction |
Pyogenic flexor tenosynovitis is a common, potentially serious hand infection. Although initial management is surgical, postoperative antibiotic strategies vary. We evaluated a protocol combining minimally invasive surgical irrigation with a short (7–10 day) course of oral antibiotics, reporting infection control and functional outcomes at six months.
Patients and methods |
In this prospective observational cohort, consecutive patients treated for pyogenic flexor tenosynovitis between 2 November 2022, and 30 October 2024 were managed as outpatients or with brief hospital stays. The standardized protocol comprised minimally invasive lavage followed by a single oral antibiotic course (median 8 days). Primary endpoints were treatment failure and functional status at six months (Patient-Rated Wrist Evaluation, PRWE). We analysed failure rates, predictors of failure, and determinants of functional outcome.
Results |
One hundred and forty-eight patients were included; 93% were treated on an outpatient basis. All received postoperative oral antibiotics, predominantly amoxicillin–clavulanate (96%); median duration was 8 days. Overall failure rate was 6.8%. Stage IIB phlegmon was independently associated with treatment failure (p = 0.033). At six months, 86 patients were reassessed: 74% had PRWE ≤ 10, consistent with minimal or no functional impairment. Higher phlegmon stage (p = 0.032), longer treatment delay (p = 0.013), and occurrence of treatment failure (p = 0.011) were significantly associated with worse functional outcome.
Conclusion |
For stage I and IIA pyogenic flexor tenosynovitis, outpatient management combining minimally invasive surgical lavage and a one-week oral antibiotic regimen appears safe and effective. Patients with stage IIB disease have higher failure risk and may require an adapted approach.
Le texte complet de cet article est disponible en PDF.Keywords : Pyogenic flexor tenosynovitis, Oral antibiotics, Outpatient
Plan
Vol 45 - N° 4
Article 102724- septembre 2026 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?

